search
Back to results

Phototherapy For Treatment Of Raynaud's Phenomenon

Primary Purpose

Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Blue Light Therapy
Sham Light Therapy
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Raynaud Disease

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Must have a current diagnosis by a physician of Raynaud's Phenomenon/Syndrome

Exclusion Criteria:

  • Those with active ischemic digital ulcers or gangrene as the cold exposure can be a safety hazard for them.
  • Inability of the subject to place their hands into the PTD portal because of physical size or discomfort.
  • Inability of the subject to wear protective eyewear.
  • Anyone, who in the judgement of any of the investigators, would be unable to safely complete the study procedures.
  • Females who are pregnant.
  • Adults unable to consent for any reason not explicitly stated herein.

Sites / Locations

  • University of Minnesota

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Sham First, then Experimental

Experimental First, then Sham

Arm Description

Participants in this group will receive the sham treatment first, then the experimental treatment.

Participants in this group will receive the experimental treatment first, then the sham treatment.

Outcomes

Primary Outcome Measures

Change in Visual Analog Scale (VAS) of Pain
Participants will be asked to rate their pain upon cold room exposure between treatments using a 10 centimeter visual analog scale (VAS). Outcome is reported as the mean change in VAS per arm in units of millimeters.
Change in Visual Analog Scale (VAS) of Numbness
Participants will be asked to rate their numbness upon cold room exposure between treatments using a 10 centimeter visual analog scale (VAS). Outcome is reported as the mean change in VAS per arm in units of millimeters.

Secondary Outcome Measures

Skin Temperature
Skin temperature of at least one finger will be measured and logged using a thermometer at multiple points during study visit. Outcome is reported in units of degrees Celsius.

Full Information

First Posted
May 18, 2021
Last Updated
January 4, 2023
Sponsor
University of Minnesota
search

1. Study Identification

Unique Protocol Identification Number
NCT04898036
Brief Title
Phototherapy For Treatment Of Raynaud's Phenomenon
Official Title
Phototherapy For Treatment Of Raynaud's Phenomenon
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Withdrawn
Why Stopped
no funding or staff
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine if blue light therapy can improve the symptoms of Raynaud's phenomenon, and provide parameters for ultimately designing commercial treatment devices, an investigational stationary phototherapy unit was designed and built.
Detailed Description
The purpose of this study is to test the efficacy of blue light phototherapy for the treatment of Raynaud's phenomenon (RP) in human participants. The specific aim is to see if phototherapy treatment applied to the hands will reduce the symptoms that RP participants experience. This will be measured through the use of a visual analog scale (VAS) of both pain and numbness. This study will also help to infer whether blue light phototherapy causes vasodilation through infrared thermal imaging of the hands and continuous measurement of skin temperature with a surface thermistor. Together, the visual analog scale (VAS) and infrared thermal imaging contribute to the objective of deducing whether blue light phototherapy can lead to reduced RP symptoms due to vasodilation of blood vessels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sham First, then Experimental
Arm Type
Experimental
Arm Description
Participants in this group will receive the sham treatment first, then the experimental treatment.
Arm Title
Experimental First, then Sham
Arm Type
Experimental
Arm Description
Participants in this group will receive the experimental treatment first, then the sham treatment.
Intervention Type
Device
Intervention Name(s)
Blue Light Therapy
Intervention Description
This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
Intervention Type
Device
Intervention Name(s)
Sham Light Therapy
Intervention Description
To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
Primary Outcome Measure Information:
Title
Change in Visual Analog Scale (VAS) of Pain
Description
Participants will be asked to rate their pain upon cold room exposure between treatments using a 10 centimeter visual analog scale (VAS). Outcome is reported as the mean change in VAS per arm in units of millimeters.
Time Frame
4 hours
Title
Change in Visual Analog Scale (VAS) of Numbness
Description
Participants will be asked to rate their numbness upon cold room exposure between treatments using a 10 centimeter visual analog scale (VAS). Outcome is reported as the mean change in VAS per arm in units of millimeters.
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Skin Temperature
Description
Skin temperature of at least one finger will be measured and logged using a thermometer at multiple points during study visit. Outcome is reported in units of degrees Celsius.
Time Frame
4 hours
Other Pre-specified Outcome Measures:
Title
Thermal Imaging
Description
The thermal imaging camera takes still images of the hand before and immediately after treatment. It provides a heat map (color contour) that may be probed afterwards for temperature at designated points. These points are distributed over the fingers, hand and palms. A technician manually reads the temperature in degrees Celsius and enters the values into an Excel spreadsheet designating subject, ID and date; location of measurement; and other temperature readings. These include ambient (room temperature), and outside temperature. The finger and room temperatures, in Celsius, are electronically recorded on an Omega data logger. This is interrogated later to retrieve data. Another continuous reading is obtained of the temperature inside the hand compartment (separate from internal thermoregulation measurements) to track equipment functionality.
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Must have a current diagnosis by a physician of Raynaud's Phenomenon/Syndrome Exclusion Criteria: Those with active ischemic digital ulcers or gangrene as the cold exposure can be a safety hazard for them. Inability of the subject to place their hands into the PTD portal because of physical size or discomfort. Inability of the subject to wear protective eyewear. Anyone, who in the judgement of any of the investigators, would be unable to safely complete the study procedures. Females who are pregnant. Adults unable to consent for any reason not explicitly stated herein.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jerry Molitor, MD, PhD
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Phototherapy For Treatment Of Raynaud's Phenomenon

We'll reach out to this number within 24 hrs